KALA

Kala Pharmaceuticals Inc.

Price

$0.19

return (12m)

-99.60%

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

KALA price

Kala Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment KALA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-66.57%

3 months

-70.36%

1 year

-99.60%

2 years

-99.93%

5 years

-100.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals KALA

Valuation

P/E

0.00

Sector -3.10

Industry -3.10

P/BV

0.00

Sector 1.77

Industry 1.77

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

4.56

Sector -216.68

Industry -216.68

EV/EBIT

4.56

Sector -46.14

Industry -46.14

P/EBITDA

0.00

Sector -21.54

Industry -21.54

P/EBIT

0.00

Sector -27.94

Industry -27.94

P/Total Assets

0.00

Sector 1.05

Industry 1.05

P/Net Current Assets

0.00

Sector -9.24

Industry -9.24

P/Working Capital

0.00

Sector -135.45

Industry -135.45

EPS

166.14

Sector -1.78

Industry -1.78

BVPS

121.95

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

0.00%

Sector 41.24%

Industry 41.24%

EBITDA Margin

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

0.00%

Sector -35.37%

Industry -35.37%

Net Profit Margins

0.00%

Sector -35.81%

Industry -35.81%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

136.23%

Sector -57.47%

Industry -57.47%

ROA

116.43%

Sector -59.48%

Industry -59.48%

ROIC

-359.10%

Sector -2,385.22%

Industry -2,385.22%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

6.88

Sector 2.92

Industry 2.92

Net Debt / EBITDA

4.57

Sector -21.38

Industry -21.38

Net Debt / EBIT

4.57

Sector -8.29

Industry -8.29

Net Debt / Equity

-0.80

Sector -33,113.00

Industry -33,113.00

Gross Debt / Equity

0.00

Sector -0.84

Industry -0.84

Equity/Assets

0.85

Sector 0.46

Industry 0.46

Liabilities/Assets

0.15

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals KALA

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Kala Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.19

Fair Value

$675.18

Upside

355,819.62%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KALA Kala Pharmaceuticals Inc.	$0.19	-99.71%	0.00%	0.00	0.00	136.23%	0.00%
PFE Pfizer Inc.	$30.11	32.57%	5.91%	38.29	1.94	5.07%	6.80%
ABBV AbbVie Inc.	$289.08	28.55%	2.40%	79.71	-84.84	-106.44%	9.81%
NVO Novo Nordisk A/S	$39.35	-24.59%	4.74%	9.57	5.08	53.11%	35.32%
MRK Merck & Co. Inc.	$148.30	80.03%	2.34%	113.15	8.55	7.56%	4.77%
AZN AstraZeneca PLC	$168.82	3.18%	1.95%	19.76	5.09	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$61.68	49.61%	4.19%	13.18	5.48	41.59%	18.87%
ZTS Zoetis Inc.	$80.04	-43.37%	2.64%	12.52	10.49	83.77%	27.69%
AMGN Amgen Inc.	$438.94	50.95%	2.29%	26.86	20.10	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$807.48	39.93%	0.47%	18.88	2.58	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$124.37	85.54%	0.00%	34.40	99.12	288.13%	24.86%
MCK McKesson Corporation	$1,030.12	31.57%	0.34%	25.91	-30.79	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$514.65	23.47%	0.00%	29.00	6.31	21.76%	35.00%
CAH Cardinal Health Inc.	$257.55	66.23%	0.81%	34.89	-21.95	-62.92%	0.67%
ARGX argenx SE	$869.72	3.09%	0.00%	13.83	3.67	26.52%	25.54%
HRMY Harmony Biosciences Holdings Inc.	$38.70	49.42%	0.00%	12.22	2.22	18.14%	18.88%
BIIB Biogen Inc.	$243.10	70.00%	0.00%	41.65	1.84	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KALA - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Kala Pharmaceuticals

Kala Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

17 years

Founded: 2009

2017

Time since IPO - 9 years

188

Employees

Kala Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $13.82 Thousand, with shareholders equity totaling $9.04 million.

The company employs approximately 188 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Kala Pharmaceuticals Inc. reported $- in revenue, generating net income of $12.32 million.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KALA.

Market cap

$13.82 Thousand

Net worth

$9.04 million

$9,044,000.00

Assets

$10.58 million

$10,582,000.00

Total Shares Outstanding

74.16 Thousand

74,000

Average Daily Trading Volume

$1.89 million

$1,891,127.50

Sector

Health Care

Industry

Biotechnology

KALA

KALA revenue and profits

Financial Results KALA

DRAG THE FRAME TO SEE MORE DATA

KALA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$1,030.12 31,36% (12M)

P/E

25.91

0.34%

ROE

-118.84%

P/BV

-30.79

CAH - Cardinal Health

$257.55 63,85% (12M)

P/E

34.89

0.81%

ROE

-62.92%

P/BV

-21.95

ABBV - AbbVie

$289.08 28,92% (12M)

P/E

79.71

2.40%

ROE

-106.44%

P/BV

-84.84

MRK - Merck & Co.

$148.30 74,22% (12M)

P/E

113.15

2.34%

ROE

7.56%

P/BV

8.55

AZN - AstraZeneca

$168.82 2,92% (12M)

P/E

19.76

1.95%

ROE

25.77%

P/BV

5.09

PFE - Pfizer

$30.11 31,72% (12M)

P/E

38.29

5.91%

ROE

5.07%

P/BV

1.94

BMY - Bristol-Myers Squibb

$61.68 46,55% (12M)

P/E

13.18

4.19%

ROE

41.59%

P/BV

5.48

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$1,030.12 31,36% (12 M)

P/L

25.91

0.34%

ROE

-118.84%

P/VP

-30.79

CAH - Cardinal Health

$257.55 63,85% (12 M)

P/L

34.89

0.81%

ROE

-62.92%

P/VP

-21.95

ABBV - AbbVie

$289.08 28,92% (12 M)

P/L

79.71

2.40%

ROE

-106.44%

P/VP

-84.84

MRK - Merck & Co.

$148.30 74,22% (12 M)

P/L

113.15

2.34%

ROE

7.56%

P/VP

8.55

AZN - AstraZeneca

$168.82 2,92% (12 M)

P/L

19.76

1.95%

ROE

25.77%

P/VP

5.09

PFE - Pfizer

$30.11 31,72% (12 M)

P/L

38.29

5.91%

ROE

5.07%

P/VP

1.94

BMY - Bristol-Myers Squibb

$61.68 46,55% (12 M)

P/L

13.18

4.19%

ROE

41.59%

P/VP

5.48

Frequently Asked Questions

What is the price of Kala Pharmaceuticals (KALA) today?

The current price of Kala Pharmaceuticals (KALA) is $0.19. The stock began the year trading around $0.56 and is currently priced at $0.19. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Kala Pharmaceuticals (KALA) pay dividends?

Kala Pharmaceuticals (KALA) did not pay dividends over the past year.

Is Kala Pharmaceuticals (KALA) a good investment?

Kala Pharmaceuticals (KALA) is currently trading at $0.19 with a P/E ratio of 0.00. This represents a 1% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -99.60%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Kala Pharmaceuticals (KALA) stock?

You can buy Kala Pharmaceuticals (KALA) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol KALA and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Kala Pharmaceuticals (KALA) yield today?

Over the past month, Kala Pharmaceuticals (KALA) has returned -66.57% — -99.60% over the past year, and -100.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Kala Pharmaceuticals (KALA) today at the current price of $0.19 your total investment would be $18.97.

Based on historical performance, the investment would have grown to approximately:

$0.08 after 1 year
$0.00 after 5 years
$18.97 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KALA

Kala Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KALA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING KALA WITH OTHER STOCK

ABOUT Kala Pharmaceuticals

Kala Pharmaceuticals Inc.

United States

17 years

2017

188

PROFIT X PRICE KALA

Financial Results KALA

KALA cash flow

Asset, Revenue and Profit Growth - KALA

KALA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions